바로가기 메뉴
본문내용 바로가기
하단내용 바로가기

메뉴보기

메뉴보기

발표연제 검색

연제번호 : P 3-122 북마크
제목 May Mannitol be a new treatment for refractory lymphedema? : A case report
소속 Hanyang University Medical Center, Department of Rehabilitation Medicine1
저자 Hyeonseong Kim1*, Si-Bog Park1†, Kyu Hoon Lee1, Mi Jung Kim1, Jaeyoung Lee1
Introduction
Lymphedema is caused by kind of fluid collection state in localized body part. Lymphatic system obstruction which cause by inherited abnormality, trauma, surgery, radiation, parasitic infection, or iatrogenic obstruction brings about edema and dermal thickening. Treatment varies from manual manipulation to surgical treatment, according to its cause. Despite the various treatments, lymphedema tends to progress slowly and refractory.
We report a case of an incidentally observed improvement in refractory lymphedema in patients treated with mannitol.

Case presentation
A 90-year-old woman with refractory lymphedema of left leg suddenly present mental changes and visited an emergency room. Computed tomography of brain revealed intracranial hemorrhage in the left hemisphere.
After admission, she had intensive care unit care for intracranial pressure control. Mannitol (20%, 50 ml per 6 hours) and Lasix (5 mg per 6 hours) were immediately given from 1 to 27 hospital days. Surgical procedure was not performed due to her family’s refusal and conservative treatment was continued. When the vital sign stabilized, she was transferred to the general ward. Her family was surprised to see her lymphedema improve. After the administration of mannitol was stopped, lymphedema gradually worsened. We had been continuing physical therapy with neurodevelopmental therapy and occupational therapy for right hemiplegia combined with lymphedema therapy, such as complex decongestive physical therapy, intermittent pneumatic compression, and short-stretch bandaging.
In 2016 when she admitted to hospital, the circumstances 10 cm and 15 cm below knee were 43 cm, 41cm each. According to her family, her lymphedema aggravated while living at home. However, after mannitol had been given for 27 days, the circumstances 10 cm and 15 cm below knee were 34 cm, 31.5 cm each.
On 47 hospital day, her lymphedema become worse despite the various treatments. The circumstances 10 cm and 15 cm below knee increased to 42 cm, 40.5 cm each. To identify the effect of mannitol for lymphedema, mannitol (20%, 50 ml per 6 hours) and Lasix (5 mg per 6 hours) were restarted from 52 to 58 hospital day. As a result, her lymphedema has been improved, and the circumstances 10 cm and 15 cm below knee decreased to 37 cm, 36 cm each on 53 hospital day. And this improvement has been maintained after mannitol and Lasix were tapered off.

Conclusion
This is the first reported case, to our knowledge, of refractory lymphedema treated with mannitol and lasix. After mannitol and lasix were administered, lower extremity lymphedema has been improved dramatically. In order to clarify the effect of mannitol on lymphedema, further studies on large-scale patients are needed.